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ABSTRACT 
Gut microbiota play an integral role in the postnatal development and maturation of the 
intestinal epithelium as well as the innate and adaptive immune system. Gut microbes 
communicate to the host via pattern recognition receptors (PRRs) which regulate 
intestinal homeostasis during health and disease. My thesis has elucidated the role of 
gut microflora and PRR-mediated signaling during inflammation, infection and tumor 
development. I have examined the relevant contributions of host-microbe crosstalk in 
the regulation of intestinal tumorigenesis (Paper I and II) and innate immune responses 
to enteric pathogens (Paper III), as well as the transcriptional regulation of gene 
expression during inflammation and cancer development (Paper IV). 
 
In Paper I, the role of microbiota-derived signals in promoting tumor growth in 
APCMin/+ mice, a mouse model of colorectal cancer (CRC) was examined. Our data 
showed that germ-free APCMin/+ mice have a reduced tumor load compared to that 
observed in APCMin/+ mice harboring gut microbiota. Further in-depth characterization 
studies suggested a role for c-Jun/JNK and myeloid cell-dependent STAT3 activation 
pathways in the acceleration of tumor growth. Thus, gut microbiota can accelerate 
tumor growth.  
 
In Paper II, the role of PRR-mediated signaling in intestinal tumorigenesis was studied. 
By introduction of a constitutively active Toll-like-receptor 4 transgene (CD4-TLR4) to 
the intestinal epithelium of APCMin/+ mice, we found a marked reduction of intestinal 
tumor burden in CD4-TLR4-APCMin/+ mice. This tumor suppression was likely due to 
the observed Cox-2 down-regulation and IFNβ induction which resulted in increased 
apoptosis of tumor cells. These results unravel a previously unrecognized role of TLR4 
signaling in modulating the balance between proliferative and apoptotic signals.  
 
In Paper III, the regulation of host innate immune responses during Salmonella 
Typhimurium induced colitis was studied. Our data demonstrated an aggravated colitis 
in infected mice lacking the innate immune regulator gene - PPAR in the intestinal 
epithelium. This increased tissue damage correlated with the elevation of lipocalin-2 
(Lcn2) expression, which promoted the stabilization of tissue degrading enzyme, 
matrix metalloproteinase 9 (MMP-9). Interestingly, Lcn2-deficient mice were markedly 
protected from S. Typhimurium induced colitis. These findings therefore illustrate how 
enteric pathogens can exploit the host’s mucosal defense mechanisms to disrupt normal 
host-microbe homeostasis, in order to ensure colonization and survival in the host.  
 
In Paper IV, I have examined the significance of histone modifications and chromatin-
binding proteins in the transcriptional regulation of T lymphocytes. Our results 
demonstrate that the bromodomain-containing protein, BRD4, is important in 
regulating Pol II Ser2-mediated transcriptional elongation in human CD4+ T cells. 
 
In conclusion, my thesis work further underscores the significant impact of gut 
microbiota mediated signaling in the regulation of intestinal homeostasis and 
tumorigenesis.    
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1 INTRODUCTION 
 
1.1 OVERVIEW OF COLORECTAL CARCINOMA 
Colorectal carcinoma (CRC) is the third most frequently diagnosed malignancy in the 
world and one of the leading causes of cancer mortality in many developed countries 
(http://globocan.iarc.fr/). While treatment for early stages of CRC, entailing the surgical 
removal of noninvasive adenomas, has been highly effective, treatment options for 
patients in advanced, debilitating stages of the disease are often limited and less 
efficient, thus leading to poor prognosis. Unfortunately, most CRC cases are usually 
diagnosed at a stage where surgical excision cannot eradicate the lesions completely 
and hence the high mortality rates. As such, a better understanding of the mechanisms 
underlying the disease pathogenesis is crucial to improve treatment outcomes.  
 
In this thesis, I define carcinogenesis as a multi-step process involving a series of 
genetic, epigenetic and environmental events that drive tumor initiation, progression to 
carcinoma, and ultimately the development of malignancy, which is the ability of the 
carcinoma to metastasize and cause death. Thus, the process of colorectal 
carcinogenesis requires multiple genetic events that lead to the inactivation of tumor 
suppressor genes and activation of oncogenes, thereby conferring neoplastic cells with 
a survival advantage and ability to escape normal regulation of growth and apoptosis.  
Here, the term ‘adenoma’ is used to describe a benign tumor that arises from epithelial 
tissues and it is usually referred to as an adenomatous polyp when it develops in the 
colon or small intestine. In contrast, a ‘carcinoma’ arises from an adenoma that has 
progressed into an invasive, malignant tumor. 
 
Current understanding of the genetic basis of CRC converges largely on mutations in 
the tumor suppressor gene, adenomatous polyposis coli (APC), as the key initiating 
event in colorectal carcinogenesis (Figure 1).1 This gene was first discovered in familial 
adenomatous polyposis (FAP), a hereditary colorectal cancer syndrome that is 
characterized by hundreds to thousands of adenomas in the colon and rectum.2,3,4  Most 
FAP patients have been demonstrated to carry germline APC mutations, majority of 
which comprise of nonsense or frameshift mutations that lead to a truncated APC 
protein with abnormal function.5 Consistent with Knudson’s “two-hit” hypothesis, FAP 
patients are predisposed but also require a ‘second hit’ to develop CRC.6 This ‘second 
hit’ is usually a somatic mutation of the wild-type APC allele or loss of heterozygosity 
at the APC locus and appears to be dependent on the nature of the first hit.7,8  
 
While germline mutations in the APC gene accounts for ~1% of all CRC cases, a vast 
majority of sporadic colorectal tumors also acquire somatic APC mutations (Table 
1).9,10 These studies thus provide evidence that somatic APC mutations, resulting in loss 
of APC function, form a critical initiating step in the development of colorectal tumors. 
Additional mutations in genes such as K-RAS, p53, and mismatch repair (MMR) genes 
contribute to drive the progression of these adenomas to malignancy (Figure 1).1,11,12 
Meanwhile, there exists a small minority of CRC cases that are caused by mutations 
distinct from the APC locus. One example is hereditary non-polyposis colorectal cancer 
(HNPCC), which accounts for 2-4% of CRC cases and is caused by mutations in DNA 
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mismatch repair genes.1 In addition, mutations in the β-catenin gene, CTNNB1, have 
been observed in a large proportion of CRCs that do not harbor APC mutations.13,14  
 
 
Table 1. Incidence and types of APC mutations in CRC. Source:1  
 
 
Besides a well-defined genetic etiology, it is also widely recognized that an elevated 
risk of colon carcinogenesis is associated with chronic colonic inflammation (i.e. 
colitis) such as the inflammatory bowel disease (IBD) syndromes, ulcerative colitis 
(UC) and Crohn’s disease (CD).15,16 More than 20% of IBD patients develop colitis-
associated cancer (CAC), a CRC subtype that is difficult to treat and is associated with 
high mortality.17 In majority of such IBD cases, the affected individuals progress to a 
relapsing and chronic disease characterized by persistent inflammation of the 
gastrointestinal mucosa, rectal bleeding and diarrhea.  
 
Chronic inflammation can promote the development of CAC through the production of 
oxidative stress, which increases the risk of DNA damage and accumulation of 
mutations in genes involved in carcinogenic pathways such as p53, k-ras and DNA 
mismatch repair.18 The intestinal microbiota and inflammatory mediators such as 
growth and survival promoting cytokines have also been strongly implicated in the 
pathogenesis of CAC.17,19 In contrast to the ‘adenoma-carcinoma’ transition found in 
FAP and sporadic CRCs, CRCs that occur in IBD typically develop in an 
‘inflammation-dysplasia-carcinoma’ sequence and the neoplastic lesions usually 
manifest within mucosal regions with colonic inflammation (Figure 2).18 Although loss 
of APC function is a major predisposing event in FAP and sporadic CRCs, it is rarely 
detected in colitic mucosa with null to low-grade dysplasia and usually occurs later in 
the development of CAC.15 On the contrary, loss of p53 function appears to be an 
instrumental step in the progression of CAC, with allelic deletion of p53 detected in 
~50-80% of colitis-associated tumors and frequent p53 mutations found in colitic, 
nondysplastic mucosa.15  
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Figure 1. Model of the major genetic alterations linked to the initiation and progression 
of CRC. Source:1  
 
 
 
 
Figure 2. Molecular pathogenesis of colitis-associated colon cancer. Adapted and 
modified from:15  
 
 
1.2 BIOLOGICAL FUNCTIONS OF APC IN REGULATION OF WNT/Β-
CATENIN PATHWAY 
 
The APC protein is a multifunctional protein that has been extensively studied for its 
role in colorectal tumorigenesis. Besides its well-recognized role in the regulation of 
the Wnt/β-catenin signaling pathway, APC also has important functions in cell 
migration and adhesion, chromosome segregation, microtubule binding and apoptosis.20 
In this summary, I focus mainly on the role of APC in the context of CRC. 
 
The connection between APC and Wnt signaling emerged soon after the discovery of 
the interaction between the APC protein and β-catenin.21,22 Although its specific 
molecular activity still remains unresolved, APC is known from studies on CRC to be 
essential for the proper functioning of the destruction complex that regulates Wnt/β-
catenin signaling. This signaling cascade is a key regulator of embryonic development 
and adult homeostasis, being one of the fundamental mechanisms governing cell 
proliferation, cell polarity and cell fate determination.23 In the gut, the canonical Wnt/β-
catenin pathway plays an essential role in regulating intestinal homeostasis and stem 
cell self-renewal. As such, it is not surprising that this signaling pathway is often 
 Gut microflora Inflammatory 
mediators 
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exploited during intestinal tumorigenesis as well as in other cancers, where Wnt 
pathway mutations leading to the inappropriate stabilization of β-catenin are frequently 
observed.24 Notably, inactivating mutations or truncations in the APC gene are detected 
in a large proportion of tumors from FAP and sporadic CRC cases as discussed earlier. 
 
This high frequency of APC mutations in CRC progression arises predominantly from 
the ‘gatekeeper’ function of the APC protein in controlling intestinal epithelial cell 
proliferation, through its regulation of β-catenin-mediated transcriptional activation. In 
the absence of Wnt ligands, cytoplasmic β-catenin is constantly phosphorylated and 
targeted for degradation by a complex comprising of APC, axin, casein kinase 1 (CK1) 
and glycogen synthase kinase 3 (GSK3).24,25 Upon binding of Wnt ligand to its Frizzled 
receptor, the canonical Wnt signaling cascade is activated, resulting in inhibition of the 
degradation complex and thus stabilization of β-catenin. Subsequently, the 
accumulation of newly synthesized, unphosphorylated β-catenin triggers its 
translocation to the nucleus, where it acts as a co-activator for transcription factors of 
the T-cell factor/lymphoid-enhancing factor (TCF/LEF) family through displacement 
of the Groucho transcriptional repressors from Tcf/Lef (Figure 3).24,25 Thus, in the 
setting of intestinal tumorigenesis, the dysfunction of APC facilitates constitutive 
activation of the TCF/β-catenin transcriptional complex, thereby inducing the 
expression of various cell-cycle regulatory genes such as c-Myc and cyclin D1 that lead 
to aberrant cell proliferation.26,27  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The canonical Wnt/β-catenin pathway. When the Frizzled (Fz)/LRP 
coreceptor complex is not bound by Wnt ligands, CK1 and GSK3 phosphorylate β-
catenin. Phosphorylated β-catenin is targeted for proteasomal degradation by β-TrCP, a 
component of an E3 ubiquitin ligase. Thus, TCF remains bound to Groucho in the 
nucleus and the transcription of Wnt target genes is inhibited. Upon Wnt binding to 
Frizzled/LRP, the kinase activity of the destruction complex is inhibited by interaction 
of axin with LRP and/or Dishevelled (Dvl). As a result, β-catenin is stabilized and it 
accumulates and travels into the nucleus where it displaces Groucho from TCF to 
activate transcription of Wnt target genes. Source:28 
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1.3 BENEFITS AND LIMITATIONS OF THE APCMIN/+ MOUSE MODEL 
 
In my study, I used the APCMin/+ mouse as a model of CRC. The APCMin/+ mouse 
model carries a germline truncation at codon 850 of the APC gene, closely resembling 
inactivating APC mutations found in FAP patients. Heterozygous APCMin/+ mice 
develop numerous adenomatous polyps in the small intestine, and hence the term ‘Min’ 
for multiple intestinal neoplasia, following a somatic event (the ‘second hit’) involving 
loss of the wild-type allele (i.e. loss of heterozygosity).29,30 Thus, the APCMin/+ mouse 
serves as a valuable experimental tool for gaining insights into the molecular pathways 
of intestinal tumorigenesis, for identifying environmental factors and the manipulation 
of genes influencing tumor progression, and for evaluating novel therapeutic strategies 
of human CRC. 
 
Despite its broad utility, this mouse model also has limitations for modeling human 
CRC. In particular, these mice typically manifest small intestinal lesions whereas 
sporadic and inherited intestinal tumors in humans are predominantly found in the 
colon and rectum.29,31 Moreover, APCMin/+ mice rarely develop carcinomas due to death 
arising from the progressive onset of anemia and malnourishment as a consequence of 
multiple intestinal lesions, by 140 days of age. As such, the APCMin/+ model can only 
partially recapitulate some of the key features observed in advanced forms of human 
CRC.  
 
Deregulation of the Wnt/β-catenin pathway has generally been considered to be one of 
the key events underlying the initiation and progression of CRC as well as APCMin/+ 
intestinal tumorigenesis. However till date, several studies have identified various 
modifiers to this canonical signaling cascade. Two notable examples are Mom1 
(Modifier of Min 1) and Mom2 (Modifier of Min 2), two modifier loci which have been 
found to influence tumor size and multiplicity in APCMin/+ mice.32,33 Through 
backcrosses of APCMin/+ mice from different strains, Mom1 and Mom2 were identified 
to strongly suppress Min-induced tumorigenesis, providing evidence that genetic 
background can significantly impact on the penetrance of the APCMin/+ mutation. 32,33 
Besides the two genetic modifiers, various non-canonical protein complexes such as the 
transcriptional corepressor C-terminal binding protein-1 (CtBP1), AP-1 transcription 
factor c-Jun and KRAS have also been demonstrated to influence the oncogenic 
activity of stabilized β-catenin.34,35  
 
 
1.4 INFLAMMATION AND COLON CANCER 
 
The connection between inflammation and cancer is well recognized and a plethora of 
supporting evidence from genetic, pharmacological and epidemiological studies has 
been generated over the past decade. Epidemiological studies illustrate a predisposition 
to cancer when tissues are chronically inflamed and the long-term administration of 
non-steroidal anti-inflammatory drugs (NSAIDs) has been shown to reduce the risk of 
various cancers.36 Moreover, the critical contributions of major inflammatory pathways 
and tumor-infiltrating immune cells in tumor promotion have been extensively 
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investigated by numerous studies, using a range of genetic and pharmacological 
manipulations. 
 
There are various triggers of chronic inflammation that can promote cancer 
development and progression. Microbial infection may be one such trigger that 
precedes tumor development and the inflammatory response arises from normal host 
defense mechanisms of pathogen elimination. Immune deregulation and autoimmune 
disorders such as IBD is another type of chronic inflammation that elevates the risk of 
developing cancer.37 Environmental exposure to carcinogenic substances and irritants 
can also induce persistent inflammatory mechanisms that have a tumor-promoting 
effect.38 The connection between inflammation and cancer can be broadly classified 
into two major pathways: (1) an extrinsic pathway which is driven by non-resolving, 
inflammatory conditions (such as IBD) that accelerate cancer development and (2) an 
intrinsic pathway which is driven by genetic alterations in oncogenic or tumor 
suppressor pathways that activate expression of inflammatory mediators (i.e. 
chemokines and cytokines).37  
 
Inflammation can contribute to carcinogenesis via the generation of reactive oxygen 
and nitrogen species which can induce DNA base lesions, activate signal transduction 
pathways leading to the transcriptional induction of proto-oncogenes, or modify 
proteins involved in DNA repair and apoptotic regulation.39,40 In addition, the 
production of pro-inflammatory cytokines, chemokines and growth factors by 
infiltrating immune cells in the tumor microenvironment enhances cell proliferation, 
survival and migration, as well as angiogenesis, which can thereby promote tumor 
growth and progression.41  
 
In the context of CRC, chronic inflammation is intimately linked to colon 
carcinogenesis. IBD patients have an elevated risk for the development of CAC and 
cancer susceptibility increases with the duration and extent of mucosal 
inflammation.15,42 Moreover, a robust inflammatory infiltrate and heightened pro-
inflammatory cytokine expression profile can also be detected in colorectal tumors 
from sporadic CRCs.17,43 In the APCMin/+ setting of spontaneous intestinal 
tumorigenesis, E. Huang and colleagues have demonstrated the strong connection 
between intestinal inflammation and colon carcinogenesis through use of the 
interleukin-10 (IL-10)-deficient mouse model of IBD.44 IL-10 deficient mice develop 
colitis spontaneously and the breeding of APCMin/+ mice into the IL-10 null background 
resulted in an increased incidence of colonic tumors.44 Furthermore, the development of 
colonic dysplasia or carcinoma correlated with the severity of colonic inflammation,44 
thereby reaffirming the crucial role of inflammation in the acceleration of adenoma 
formation and progression to carcinomas. 
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1.4.1 Key signaling pathways connecting inflammation and colon 
cancer 
 
1.4.1.1 The canonical IKKβ- NF-κB pathway 
One major signaling pathway that links inflammation and CRC is orchestrated through 
the activation of nuclear factor κB, NF-κB. Being a central transcriptional regulator of 
innate immune and inflammatory responses, NF-κB regulates the expression of various 
cytokines, cell cycle and anti-apoptotic genes. Thus, NF-κB activation can drive the 
proliferation of premalignant cells and enhance their survival via induction of anti-
apoptotic responses. In addition, NF-κB can induce the expression of genes encoding 
adhesion molecules, angiogenic factors, inducible nitric oxide synthase and key 
enzymes of the prostaglandin synthesis pathway, which have a promoting effect in 
tumor progression. As such, activation of NF-κB is one of the key hallmarks of various 
inflammation-associated cancers.37,45  
 
In an elegant study by F. Greten and colleagues, they examined the role of the 
canonical NF-κB activation pathway in both intestinal epithelial cells and myeloid cells 
during colitis-associated colon carcinogenesis. Using enterocyte-specific ablation of the 
IκB kinase (IKKβ) complex, which facilitates NF-κB nuclear translocation via 
phosphorylation and thus ubiquitin-targeted degradation of NF-κB bound IκBs, the 
investigators showed a markedly reduced incidence of CAC tumors without an effect 
on tumor size.46 However, the inactivation of IKKβ in enterocytes did not reduce 
intestinal inflammation during acute or chronic colitis and the reduced tumor load was 
instead found to be associated with enhanced epithelial apoptosis during early tumor 
promotion.46 These findings thus suggest that NF-κB activation in enterocytes 
contributes to tumor initiation and promotion through apoptotic inhibition rather than 
inflammation.  
 
The investigators subsequently proceeded to address the role of the IKKβ-dependent 
NF-κB activation pathway in myeloid cells through specific ablation of IKKβ in 
myeloid cells. Interestingly, they found that this deletion led to a significant reduction 
in both tumor incidence and size without affecting apoptosis.46 The decreased tumor 
growth following myeloid IKKβ deletion was linked to the diminished expression of 
proinflammatory cytokines rather than increased apoptosis, thereby suggesting that 
IKKβ-dependent NF-κB signaling in myeloid cells promotes tumor growth through the 
production of tumor-promoting paracrine factors.46 This study thus illustrates the 
critical involvement of the canonical IKKβ-NF-κB signaling cascade in connecting 
inflammation and colon carcinogenesis, through its distinct tumor-promoting effects on 
the epithelial and myeloid compartments of the intestine. 
 
More recently, two studies further analyzed the effect of chronic NF-κB activation in 
the development of intestinal tumorigenesis using gut-specific transgenic activation of 
IKKβ.47,48 Notably, the persistent IKKβ-driven activation of NF-κB in intestinal 
epithelial cells led to the spontaneous development of intestinal adenomas in aged mice 
despite the lack of destructive colonic inflammation. 47,48 In one study, the investigators 
showed enhanced chemical- and APC mutation-mediated tumorigenesis following 
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constitutive NF-κB activation in the intestinal epithelium.47 This was found to be 
associated with increased β-catenin activation, hyperproliferation and elevated 
expression of stem cell markers, thus illustrating the synergy of IKKβ-NF-κB signaling 
with Wnt signaling in tumor initiation and promotion.47 Moreover, the persistent 
activation of NF-κB in intestinal epithelial cells resulted in the production of cytokines 
and chemokines that triggered increased recruitment of myeloid cells as well as 
activation of stromal fibroblasts, both of which contributed to a tumor-promoting 
microenvironment.47 In the second study, chronic epithelial NF-κB activation led to 
accelerated intestinal tumorigenesis in mice carrying a gut-specific allelic deletion of 
APC.48 This elevated tumor initiation rate in the gut was found to be linked to increased 
oxidative DNA lesions,48 thereby illustrating another mechanism by which chronic 
inflammation can contribute to intestinal tumorigenesis. As such, there is accumulating 
evidence from various genetic knockout or constitutively active transgenic models that 
support the unequivocal role of IKKβ-NF-κB signaling in driving colon cancer. 
 
 
1.4.1.2 The gp130-JAK/STAT3 signaling pathway 
Similar to NF-ĸB, the signal transducer and activator of transcription 3 (STAT3) also 
represents a point of convergence for various pro-oncogenic signaling pathways. 
Notably, STAT3 is a major transcription factor regulating genes involved in cell 
proliferation and survival pathways, as well as immunosuppressive and anti-apoptotic 
processes,49,50 which can intersect with multiple carcinogenic pathways. It is frequently 
found to be aberrantly activated in various epithelial tumors and tumor-associated 
myeloid cells.51-54 Moreover, there appears to be a significant correlation between 
constitutive STAT3 activation and poor clinical outcome or pathological features of 
various cancers including CRC.55-59  
 
STAT3 is a major transcription factor that can promote cell proliferation and survival 
through regulating genes involved in cell cycle progression, such as c-Myc and cyclin 
D1,and inhibition of apoptosis, such as Bcl-2 and Bcl-xL.36,49 Thus, the deregulated or 
persistent activation of STAT3 is often connected to the pathogenesis of many human 
cancers. In the context of CRC, constitutively active STAT3 was found to be abundant 
in transformed, dedifferentiated cells as well as infiltrating lymphocytes of CRC 
biopsies.60 Furthermore, the induction of STAT3 activity in colon carcinoma cells 
resulted in accelerated proliferation while blockade of STAT3 activation in colon 
carcinoma xenograft tumors led to a significant reduction of tumor growth.60 Hence, 
persistently activated STAT3 is a positive regulator of cell proliferation and tumor 
growth in CRC. 
 
Besides its effect on tumor cell proliferation and survival, the persistent activation of 
STAT3 also mediates tumor-promoting inflammation through its dual role in driving 
pro-oncogenic inflammatory pathways and suppression of anti-tumor immunity. 
Notably, STAT3 signaling is highly interconnected with the canonical NF-ĸB 
activation pathway as well as the interleukin-6 (IL-6)-gp130-Janus kinase (JAK) 
signaling cascade. This is well illustrated in a study by Hua Yu’s group, who showed 
that constitutively activated STAT3 is necessary for the maintenance of constitutive 
NF-ĸB activity in tumors and tumor-associated myeloid cells.61 Importantly, STAT3 
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interacts directly with NF-ĸB (RelA) and prolongs its nuclear retention through 
mediating RelA acetylation.61 These findings thereby reveal the cooperativity between 
the two major transcription factors in stimulating a repertoire of proliferative and 
prosurvival genes which are essential for tumor promotion. 
 
Interestingly, several inflammatory factors encoded by NF-ĸB target genes, such as 
interleukin-6 (IL-6), are major activators of STAT3. IL-6 is a multifunctional cytokine 
that acts on both epithelial and immune cells. In particular, it is known to drive STAT3 
activation through interaction with the membrane-associated gp130 subunit, thereby 
activating Janus kinases (JAKs) and one of the downstream effectors - STAT3. In the 
aspect of colitis-associated tumorigenesis, the role of IL-6 as a critical tumor promoter, 
acting via stimulation of gp130-mediated STAT3 activation, was well illustrated by 
two elegant studies. Using mice deficient for STAT3 in intestinal epithelial cells, both 
studies showed the remarkable reduction in CAC tumor size and incidence following 
STAT3 ablation in the intestinal epithelium.62,63  
 
Notably, one study by S. Grivennikov and coworkers demonstrated that IL-6 knockout 
mice were similarly protected from CAC tumorigenesis and bone marrow-derived 
myeloid cells were one of the main producers of IL-6.63 Consistent with the stimulatory 
effect of IL-6 on epithelial cell proliferation and survival, the exogenous administration 
of IL-6 to these mice during early CAC induction triggered an increase in tumor 
multiplicity while IL-6 administration during the late stages of CAC growth led to an 
increase in tumor burden.63 Moreover, IL-6 deficient mice displayed reduced levels of 
activated STAT3 in intestinal epithelial cells during colitis and CAC induction.63  
 
In the second study, J. Bollrath and colleagues further showed that the hyperactivation 
of STAT3 in mice carrying mutant gp130 receptor resulted in the acceleration of CAC 
tumor incidence and growth.62 In contrast, the reduction of CAC tumors in mice 
lacking STAT3 in intestinal epithelial cells correlated with increased epithelial 
apoptosis during early CAC induction.62 Mice deficient in epithelial STAT3 also 
exhibited more profound mucosal damage and apoptosis during colitis induction,62,63 
thereby implying the important role of STAT3 in epithelial proliferation and apoptotic 
inhibition which can be utilized for tumor formation and growth. As such, the two 
studies reveal the critical role of epithelial STAT3 activation in the transduction of 
tumor-promoting signals from IL-6 in the tumor microenvironment during CAC 
tumorigenesis. 
 
STAT3 also has important functions in myeloid cells, most notably in the suppression 
of anti-tumor immunity, thereby attesting to its relevance in tumor promotion. In 
particular, the ablation of STAT3 in hematopoietic cells has been demonstrated to 
inhibit tumor growth and progression via the induction of an intrinsic tumor immune 
surveillance response.53 STAT3 activity in tumors is known to mediate immune 
suppression through the downregulation of proinflammatory cytokines that are crucial 
for dendritic cell (DC) activation, which in turn modulates T-cell immunity.64 
Furthermore, STAT3 signaling can stimulate the production of several 
immunosuppressive factors such as IL-10 and vascular endothelial growth factor 
(VEGF), which are also activators of STAT3.65 Thus, targeting STAT3 in 
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hematopoietic cells, via genetic ablation or use of a specific inhibitor, resulted in 
enhanced antitumor immune responses leading to tumor regression.53  
 
Interestingly, the oncogenic functions of STAT3 can also be mediated through its 
cooperation with c-Jun, a proto-oncoprotein which forms a component of the activator 
protein 1 (AP-1) transcription factor complex. In a study by V. Ivanov and colleagues, 
the combined activity of STAT3 and c-Jun in melanoma cells was found to suppress 
the transcription of Fas, a receptor that participates in the induction of apoptosis.66 This 
downregulation of Fas surface expression was inversely correlated with the sensitivity 
of the melanoma tumors to Fas-ligand mediated apoptosis, thereby implicating the 
cooperative role of STAT3 and c-Jun in mediating tumor resistance to therapy-targeted 
cell death.66  
 
 
1.4.1.3 The JNK-c-Jun/AP-1 pathway 
c-Jun is a member of the AP-1 family of basic leucine-zipper proteins or transcription 
factors that regulates the expression of genes involved in cell cycle progression, 
apoptosis and tumorigenesis.67,68 It can form functional transcription factors via 
heterodimerization with other members of the AP-1 group. The c-Jun/AP-1 signaling 
pathway is triggered by various stimuli such as cytokines, growth factors and 
extracellular stresses, and is mediated by c-Jun N-terminal kinases (JNKs).69 Notably, 
JNKs activate AP-1 signaling by phosphorylating critical serine and threonine residues 
found within the transactivation domain of c-Jun, thereby stimulating the transcription 
of various target genes including c-jun itself.69  
 
The oncogenic ability of c-Jun is well established more than a decade ago from 
numerous studies demonstrating its cooperation with Ras, another known oncoprotein, 
in driving cell transformation, a process that is also dependent on JNK-mediated N-
terminal phosphorylation of c-Jun.70-74 Meanwhile, the significant contribution of JNK-
dependent c-Jun phosphorylation in the promotion of intestinal tumorigenesis has been 
implicated in at least two studies by Axel Behrens’s group. Using APCMin/+ mice which 
carry either a genetic abrogation of c-Jun N-terminal phosphorylation or a gut-specific 
conditional inactivation of c-Jun, the investigators revealed a significant reduction in 
tumor incidence and burden as well as prolonged lifespan in these mice with impaired 
c-Jun phosphorylation or c-Jun deficiency.35 This reduced tumor load was correlated 
with the decreased proliferation index in adenoma cells lacking c-Jun function,35 thus 
highlighting the critical role of JNK-mediated c-Jun N-terminal phosphorylation in 
oncogenic transformation and development. Importantly, the group showed a 
phosphorylation-dependent interaction between c-Jun and the transcription factor TCF4 
as a potential molecular mechanism regulating APCMin/+ intestinal tumorigenesis.35 
This transcriptional cooperation between TCF4 and c-Jun was also dependent on β-
catenin activation, thereby providing evidence for the integration of the JNK-c-Jun/AP-
1 and TCF/β-catenin pathways, which can both be activated independently by Wnt 
signaling.35  
 
The investigators then proceeded to further characterize the significance of JNK 
activation in the gut by generating transgenic mice overexpressing constitutively active 
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JNK proteins in intestinal epithelial cells. Intriguingly, augmented JNK signaling 
resulted in increased intestinal cell proliferation and villus length.75 This was linked to 
the increased JNK activity and hence phosphorylated c-Jun in crypt base columnar 
(CBC) progenitor cells, as well as the concomitant stimulation of Wnt signaling in 
progenitor cells.75 Moreover, tcf4 was found to be a direct c-Jun target gene and its 
expression could be augmented by JNK signaling, henceforth illustrating a synergistic 
interaction between JNK and Wnt pathways.75 Interestingly, hyperactivation of JNK 
signaling in the gut accelerated colitis-triggered tumorigenesis but did not affect 
APCMin/+ tumor development.75 These differential effects were attributed by the authors 
to the possible saturation in endogenous levels of phosphorylated c-Jun in APCMin/+ 
adenomas whilst colitis-induced tumors had much lower amounts of c-Jun 
phosphorylation prior to transgenic JNK activation.75 The two studies thus emphasize 
the critical role of JNK-dependent c-Jun/AP-1 signaling in the promotion of both 
spontaneous and colitis-associated intestinal tumorigenesis, that represents a relevant 
therapeutic target for human CRCs.  
 
 
1.4.2 Role of tumor-infiltrating immune cells in CRC progression 
 
It is well accepted that inflammation promotes the progression of epithelial-derived 
tumors indirectly via activation of inflammatory cells within the tumor 
microenvironment.76 Emerging evidence from various animal models targeting myeloid 
cells has suggested that the cross-talk between epithelial cells and inflammatory cells is 
crucial for inflammation-dependent tumor development. The role of activated NF-κB in 
myeloid cells during colitis-associated tumor initiation and progression in the gut for 
instance, has been addressed in the earlier described study.46  
 
Besides cancer cells and their surrounding stroma such as fibroblasts, endothelial cells 
and mesenchymal cells, the tumor microenvironment contains various types of immune 
cells from the innate and adaptive immunity. These immune cells include macrophages, 
neutrophils, myeloid-derived suppressor cells, dendritic cells, natural killer cells, T and 
B lymphocytes, and they can produce cytokines and chemokines that either promote or 
modulate tumor growth. Tumor associated macrophages (TAMs) are the most common 
type of immune cells found within the tumor microenvironment. Although TAMs can 
produce cytokines that induce tumor cell killing, they are mostly known for their tumor 
growth promoting functions.77 These myeloid cells secrete various cytokines, 
chemokines and reactive oxygen species which can promote mutagenesis, proliferation 
and survival of premalignant cells, as well as tumor angiogenesis. The production of 
IL-6 by activated myeloid cells in the tumor infiltrate for instance, has been implicated 
in the initiation and progression of colitis-associated tumors as discussed previously.63 
As such, understanding the origin, mechanisms of recruitment and immunosuppressive 
functions of this immune cell subset is relevant for the future development of 
therapeutic targets for human CRC. 
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1.5 HOST-MICROBE INTERACTIONS IN NORMAL INTESTINAL 
HOMEOSTASIS AND DISEASE 
 
The mammalian gastrointestinal tract harbors a diverse and dynamic community of 
microorganisms, collectively termed the microbiota or microflora, which interact 
symbiotically with their host.78,79 Several important functions of gut microbiota in host 
physiology have been described, namely the regulation of nutrient acquisition,80 
gastrointestinal maturation,81 mucosal barrier fortification,82 angiogenesis,83 and the 
development of innate and adaptive immunity.84-86  
 
Despite the beneficial contributions of commensal microbiota to intestinal homeostasis 
and host immunity, they pose a major threat to the host during pathological states 
where the integrity of the mucosal barrier is breached. In such scenarios, the disease 
pathogenesis is usually promoted by an elevated immune response to the intestinal 
microflora such as that observed in IBD. The aberrant epithelial barrier facilitates the 
increased translocation of both pathogenic and commensal microbes to the lamina 
propria, leading to the persistent activation of resident inflammatory cells. Thus, even 
though the host normally develops a variety of tolerogenic mechanisms to maintain a 
symbiotic coexistence with the commensal microbiota, this delicate balance is 
disrupted during chronic intestinal inflammation arising from the loss of epithelial 
barrier integrity. This often leads to the development of a dysbiotic microbiotal 
community, which further perpetuates the inflammation, immune deregulation and pro-
carcinogenic events that facilitate CRC development (Figure 4). 
 
Interestingly, the correlation between gut microflora and human diseases has been 
implicated in a variety of ailments including metabolic disorders,87-90 IBD,91  and 
CRC,15,92 whereby alterations in microbial composition are linked to disease. Although 
an altered microbiotal community may be a consequence rather than a cause of disease, 
the ability to transmit the colitogenic activity of an altered microbiota in a variety of 
cross-fostering and co-housing studies have implicated the active role of a dysbiotic 
microbial community in disease pathogenesis.93 Moreover, the composition of 
commensal microbiota can regulate the differentiation of lamina propria immune cells, 
thereby impacting on intestinal tolerance, immune responses and susceptibility to 
IBD.94 As such, there exists a strong causal link between a dysbiotic microbiota and 
gastrointestinal diseases, particularly IBD and CRC.   
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Figure 4. A balanced microbiota community supports proper mucosal barrier function 
and maintenance of intestinal homeostasis in a healthy host. In contrast, microbial 
dysbiosis leads to the prevalence of adherent/invasive species over protective 
commensals, thus fostering dysregulated immune responses and inflammation, loss of 
barrier function and cell cycle control, as well as increased genetic alterations in a 
susceptible host. Thus a dysbiotic microbiota promotes IBD and the development of 
CRC. Source:95  
 
 
1.5.1 Impact of gut microflora on intestinal inflammation and 
tumorigenesis  
 
Disruption of the homeostasis of intestinal microflora can promote gastrointestinal 
diseases such as IBD and CRC. Microbial dysbiosis, characterized by changes in the 
abundance, diversity and stability of commensal bacteria, can impact significantly on 
the innate and adaptive immune responses of the host, thus leading to disease. For 
instance, one of the multifactorial mechanisms underlying the pathogenesis of IBD, 
which can be triggered by an altered mucosal barrier function, is the loss of tolerance to 
commensal microbes and enhanced immune response to bacterial antigens.16 In 
addition, in a genetically susceptible or immunocompromised host, the presence of gut 
microflora can promote intestinal inflammation. This is observed in many mouse 
models of IBD whereby the administration of antibiotics or rederivation of mice into 
germ-free conditions ameliorates disease severity.96,97  
 
Several enteric microbes have been demonstrated to contribute to IBD and CRC, using 
a variety of mechanisms including the activation of inflammatory pathways, induction 
of oxidative stress and shift in diversity of commensal species.17 Notably, at least three 
distinct bacterial pathogens have been found to promote colon tumorigenesis in the 
genetically susceptible, APCMin/+mouse model. In a study by Cynthia Sears’s group, the 
human colonic bacterium, enterotoxigenic Bacteriodes fragilis (ETBF), was found to 
chronically colonize APCMin/+ mice, triggering colitis and accelerating colon 
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tumorigenesis via a STAT3- and TH17-dependent pathway in these mice.98 In contrast, 
non-toxigenic B. fragilis colonized APCMin/+ mice similarly but did not induce intestinal 
inflammation nor affect colonic tumor incidence.98 In another study by David 
Schauer’s group, Citrobacter rodentium infection was shown to promote colon tumor 
formation in APCMin/+ mice.99 In the third study, the enterohepatic bacterial pathogen, 
Helicobacter hepaticus, was demonstrated to increase colonic tumor incidence in 
BALB/c-Rag2-/- APCMin/+ mice which have an altered immune function.100  
 
 
1.5.2 Pattern recognition receptors: Key mediators of host-microbe 
signaling that influence cancer and inflammation in the gut  
 
Two major classes of pattern recognition receptors (PRRs) that play a central role in 
host-microbial signaling are the Toll-like receptors (TLRs) and nucleotide-binding 
oligomerization domain (Nod)-like receptors (NLRs). They recognize a variety of 
broadly conserved microbial components and mediate various signal transduction 
processes in the host, thus impacting on host physiology and disease. In this thesis, I 
shall focus mainly on the role of TLRs in intestinal homeostasis and disease. 
 
 
1.5.2.1 Role of TLRs in the regulation of intestinal epithelial homeostasis, mucosal 
barrier fortification and inflammation 
 
Commensal microflora has been long implicated to play a significant role in regulating 
mucosal barrier functions. This was illustrated by Kitajima S. and co-workers who 
showed the increased susceptibility of germ-free mice to colonic epithelial injury 
induced by dextran sulphate sodium (DSS) as compared to conventionalized mice.101 In 
another study by Jeffrey Gordon’s group, colonization of a single commensal 
bacterium, Bacteroides thetaiotaomicron, in germ-free mice for less than two weeks 
was sufficient to trigger IgA responses and the expression of genes involved in mucosal 
barrier fortification.102 These findings thus support the critical contribution of intestinal 
microbiota in the regulation of epithelial homeostasis and mucosal barrier functions. 
 
In particular, the recognition of microbiota by TLRs has been well documented to be 
critical for the maintenance of intestinal epithelial integrity and homeostasis. Mice 
deficient in TLRs and the major signaling adaptor protein of TLRs, MyD88, have 
increased susceptibility to DSS-induced colitis.103-105 This augmented severity to DSS-
mediated colonic epithelial injury observed in TLR2-, TLR4- and MyD88- deficient 
mice was mainly attributed to the defective production of cytoprotective and reparative 
factors, as well as tight-junction defects in the intestinal epithelial barrier.103,105 These 
findings illustrate the crucial dependence on TLR/MyD88-mediated microbial 
signaling in the maintenance of intestinal epithelial barrier integrity against injury.  
 
In further support of the protective role of microbiota, the depletion of microflora in 
wild-type (WT) and TLR-deficient mice via broad spectrum antibiotic treatment not 
only rendered WT mice more sensitive to DSS-induced colitis, but also further 
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aggravated DSS-induced colonic epithelial damage in TLR-deficient mice leading to 
increased mortality.103 Notably, oral administration of lipopolysaccharide (LPS), a 
gram-negative bacterial component also known to be a TLR4 agonist, to wild-type and 
TLR2-deficient DSS-treated mice ameliorated the severity of mucosal injury.103 Oral 
treatment of WT DSS-mice with a TLR2 ligand also restored tight-junction associated 
integrity of the intestinal epithelium, thus mitigating mucosal injury and 
inflammation.105 Taken together, these studies highlight the importance of microbiota 
and MyD88-dependent TLR signaling in maintaining mucosal barrier integrity and 
triggering epithelial cell proliferation or regenerative processes upon injury. 
 
However, one major limitation of using these animal knockout models is the inability to 
define the precise contributions of various cell types in the intestinal compartment in 
injury-triggered epithelial proliferation. A number of more recent studies have since 
progressed to identify the role of microbial signaling in both the epithelial and stromal 
compartments of the intestine. In particular, TLR signaling via MyD88 in lamina 
propria macrophages was found to be crucial for stimulating the regenerative responses 
of colonic epithelial progenitors during epithelial injury in the gut.106 The reconstitution 
of irradiated WT mice with MyD88-deficient bone marrow resulted in a 
hypoproliferative response of these colonic epithelial progenitors to DSS-mediated 
injury whilst reconstitution of MyD88-deficient mice with WT bone marrow restored 
their epithelial regenerative capabilities.106  
 
These findings thus suggest that microbial signals from the intestinal lumen collaborate 
with mesenchymal-epithelial interactions to trigger proper regenerative/reparative 
responses during tissue injury in the gut. Several studies subsequently proceeded to 
further characterize the crosstalk between the mesenchymal and epithelial 
compartments that is regulated by TLR/MyD88 signaling in the intestine. Intriguingly, 
MyD88 signaling was found to be crucial for the distribution of a population of stromal 
cells expressing prostaglandin-endoperoxide synthase 2 (Ptgs2 or Cox-2), which is a 
major mediator of prostaglandin E2 (PGE2) synthesis.107 Notably, during injury, these 
Ptgs2-expressing stromal cells redistributed to enrich the crypt-base associated 
mesenchyme as well as the crypt base epithelium, where proliferative colonic epithelial 
progenitors reside. This alteration in their localization was demonstrated to require 
MyD88 signaling and was crucial for the epithelial proliferative response during DSS-
mediated tissue injury.107 These data thus reveal that MyD88-dependent signaling can 
intersect with other pathways such as Ptgs2-mediated PGE2 synthesis, which has 
important growth-stimulatory and anti-apoptotic functions that promote epithelial 
restitution. 
 
In addition to the Ptgs2-expressing stromal cells, myeloid cells have also been shown to 
be critical for the colonic epithelial response to injury.108 Importantly, MyD88 signaling 
in colonic myeloid cells was necessary to drive the proliferative response,108 thereby 
highlighting the significance of microbiotal stimulation in maintaining robustness of the 
host in mitigating perturbations in epithelial barrier integrity. Moreover, myeloid and 
non-myeloid cells in the stromal compartment play a major role in the orchestration of 
epithelial proliferative/reparative responses during barrier disruption and this is 
regulated by MyD88-mediated microbial signaling.  
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Meanwhile, the role of microbial signaling by TLRs in the epithelial compartment of 
the gut has been well addressed in studies examining regulation of the TLR4 pathway 
in intestinal inflammation, predominantly using the carcinogen, azoxymethane (AOM)-
induced, in combination with DSS treatment model of CAC. This is mainly illustrated 
by a number of studies by Maria Abreu’s group. Notably, they demonstrated that 
TLR4-deficient mice were markedly protected from colits-associated colon 
carcinogenesis as compared to WT mice, which display elevated TLR4 expression in 
their CAC tumors.109 Moreover, TLR4-deficient mice displayed a reduced pro-
inflammatory profile during DSS-induced colitis, which correlated with decreased 
severity of dysplasia and colitis-associated neoplasia.109 The group then proceeded 
further to examine the role TLR4 signaling in colonic epithelial cells through bone 
marrow transfer experiments between TLR4-deficient and WT mice. In their study, 
WT mice reconstituted with TLR4-deficient bone marrow or WT bone marrow did not 
differ in the incidence of dysplastic lesions.110 Furthermore, the size and extent of 
dysplasia were significantly greater in mice expressing TLR4 in colonic epithelial cells, 
in contrast to TLR4-deficient mice receiving WT bone marrow.110 TLR4 expression in 
colonic epithelial cells was also found to be critical for the recruitment of mucosal 
neutrophils and macrophages during AOM/DSS treatment, consistent with an increased 
inflammatory status in the intestinal mucosa that can promote colitis-associated 
tumorigenesis.110 These observations thus implicate the role of epithelial TLR4 
signaling in promoting intestinal inflammation and inflammation-associated neoplasia 
in the AOM/DSS setting.  
 
More recently, using a transgenic mouse expressing constitutively active TLR4 
specifically in the intestinal epithelium, the same group showed an augmented 
inflammatory response to DSS-induced mucosal injury in transgenic mice as compared 
to WT mice.111 These transgenic mice displayed enhanced neutrophilic infiltration and 
expression of inflammatory mediators during DSS-mediated colitis.111  Moreover, they 
also exhibited an increased susceptibility to inflammation-induced neoplasia in an 
AOM/DSS model, which was ameliorated by TLR4 antibody treatment.111 Taken 
together, the data from Abreu’s group support the role of epithelial TLR4 signaling in 
promoting intestinal inflammation during epithelial barrier disruption, especially in 
aberrant situations where it is persistently activated. While their findings of TLR4-
deficient mice during DSS-induced colitis109 appear to contradict earlier studies by 
Ruslan Medzhitov’s group,103 Abreu’s group adopted a chronic colitis model 
comprising of two cycles of DSS treatment with a recovery phase after each cycle 
while the latter group used an acute colitis model involving a single cycle of DSS 
treatment only. As such, the mucosal damage mediated by chronic inflammation or 
repeated DSS administration may outweigh the epithelial regenerative/reparative 
responses triggered by TLR4 signaling, thereby accounting for the contrasting 
treatment outcomes. These important studies thus provide an intriguing, yet incomplete 
understanding of the complex regulation of microbiotal signaling by TLRs in intestinal 
homeostasis and disease, particularly in the context of TLR4 signaling. 
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1.5.2.2 TLR4/MyD88 signaling and tumorigenesis in the gut 
 
As described in the earlier section, microbiota-derived signals mediated through TLR4 
can influence tumorigenesis in the gut. Till date, animal models mimicking microbiota 
regulation of tumor development using various treatment approaches or genetic 
manipulations reveal that there are at least two distinct facets of intestinal 
tumorigenesis that is regulated by TLR/MyD88 signaling. The first model involves 
spontaneous tumorigenesis whereby the host is genetically predisposed to the 
development of tumors, which arise in an inflammation-independent manner. In 
contrast, the second model entails intestinal tumorigenesis in an inflammation-
dependent context such as colitis. 
 
Using the genetically susceptible, APCMin/+ mouse model of intestinal tumorigenesis, 
Medzhitov’s group investigated the role of MyD88 signaling in spontaneous tumor 
development. Interestingly, genetic ablation of MyD88 in these mice resulted in a 
dramatic reduction of intestinal tumor load.112  Subsequent gene expression profiling of 
intestinal adenomas from APCMin/+ and MyD88-deficient APCMin/+ mice revealed a 
distinct set of modifier genes of intestinal tumorigenesis, as well as genes critical for 
intestinal tissue repair, that was MyD88-dependent.112 These findings thus led the 
group to conclude that MyD88 signaling pathway is essential for intestinal tumor 
progression while induction of a tissue-repair program supports the current notion of 
tumor growth as “an abnormal form of a continuous and unregulated state of tissue 
repair”.112  
 
Intriguingly, while MyD88 ablation attenuates spontaneous intestinal tumorigenesis, 
MyD88-knockout mice exhibit enhanced adenoma formation and progression to 
adenocarcinomas in a chronic inflammatory setting.113 Using the AOM/DSS model of 
CAC, Salcedo R and colleagues demonstrated the protective role of MyD88 signaling 
in the development of colitis-induced colon carcinogenesis. In their study, the impaired 
mucosal healing ability of MyD88-deficient mice led to an altered inflammatory 
environment that triggered various expression changes in genes associated with cell 
proliferation, apoptosis and DNA repair. Consistent with an altered expression profile 
that increases frequency of β-catenin mutations and promotes tumor development, 
AOM/DSS treatment resulted in an elevated incidence of colonic adenocarcinomas in 
MyD88-/- mice as compared to wild-type mice.113 Thus, in contrast to the spontaneous 
tumorigenesis model, MyD88-deficiency appears to promote colitis-associated 
tumorigenesis as a result of defective epithelial healing functions that supports 
increased intestinal inflammation during injury.  
 
In addition, these findings are further complicated by Abreu and colleagues’ data from 
TLR4-deficient mice and transgenic mice carrying constitutively active epithelial TLR4 
as elaborated earlier. This suggests that additional pathways exist between TLR4 and 
the downstream MyD88 adaptor and they can be independent of MyD88 signaling. 
This can in turn lead to very distinct functional consequences during tumor progression. 
Hence, taken together, these studies implicate the multi-faceted as well as controversial 
roles of microbial signaling mediated via PRRs in tumorigenesis. 
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As such, interfering with host-microbiota interactions through PRRs can influence 
colon carcinogenesis, likely via the microbiota’s ability to drive proinflammatory 
responses or epithelial reparative processes. While targeted ablation of the signaling 
pathways mediated by some PRRs, such as TLR4, has markedly reduced the 
occurrence of colitis-associated colon tumorigenesis, perturbing the interactions by 
downstream signaling effectors such as MyD88 can exacerbate intestinal inflammation 
and CAC instead. Meanwhile, perturbing such interactions in the setting of spontaneous 
tumorigenesis can result in very contrasting effects. Thus, the regulation of gut 
microflora in host health and disease via PRRs is complex and manipulations of PRR-
mediated recognition of microbiota need to be interpreted with care. Despite their 
potential detrimental effects to the host during dysregulated PRR signaling, host-
microbe interactions mediated through PRRs are integral for the proper development of 
host innate and adaptive immunity in the gut, as well as intestinal homeostasis and 
injury repair responses. 
 
 
1.6 ROLE OF COX-2 AND PROSTAGLANDINS IN COLON CANCER 
 
Besides the inflammatory mediators and TLRs-mediated microbial signaling discussed 
earlier, biologically active lipids such as prostaglandins and the enzymes that catalyze 
their production have also been implicated in the pathogenesis of CRC during chronic 
intestinal inflammation. Notably, pro-inflammatory prostaglandin E2 (PGE2) is well 
recognized for its role in promoting tumor growth and is frequently linked to a poor 
prognosis of CRC.114 PGE2, including other prostaglandins, is synthesized from 
arachidonic acid by cyclooxgenases (COX), which exist in at least three known 
isoforms – Cox-1, Cox-2 and Cox-3.115 While Cox-3 has been implicated as a splice 
variant of Cox-1 that lacks enzymatic activity,116 Cox-1 is believed to play a 
housekeeping role in the maintenance of basal prostaglandin levels that are essential for 
tissue homeostasis.114,115 In contrast to the constitutive expression of Cox-1 in a wide 
variety of human tissues, Cox-2 is an immediate-early response gene that is highly 
induced during inflammatory and tumorigenic settings.114,115,117  
 
Cox-2 is best known for its significant involvement in colorectal tumorigenesis, as 
illustrated by its aberrant up-regulation in a vast majority of colorectal adenomas and 
adenocarcinomas.118-121 Furthermore, elevated levels of PGE2, the downstream 
metabolite of Cox-2, have also been detected in the adenomatous polyps and 
carcinomas of FAP patients, relative to colorectal neoplasia-associated mucosa as well 
as mucosa of control subjects.122 These observations thus strongly implicate the critical 
contribution of Cox-2 in the initiation, promotion and progression of CRCs, which is 
likely to be mediated through PGE2 signaling. Consequently, a plethora of studies have 
progressed over the last decade to elucidate the causal link between Cox-2/PGE2 
signaling and intestinal tumorigenesis. 
 
Notably, the administration of exogenous PGE2 to rats resulted in an augmented 
incidence and multiplicity of AOM-induced colorectal tumors that corresponded to 
enhanced tumor cell proliferation and reduced apoptotic index.123 In APCMin/+ mice, 
PGE2 treatment was found to stimulate epithelial cell proliferation and Cox-2 
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expression in intestinal adenomas via activation of an oncogenic pathway –Ras-
mitogen–activated protein kinase (MAPK) signalling.124 These findings support the 
tumorigenic role of Cox-2 derived PGE2, which is further substantiated by the 
efficacy of Cox-2 selective NSAID, celecoxib, in reducing the occurrence of sporadic 
colorectal adenomas125 as well as the induction of colorectal tumor regression in FAP 
patients.126 The suppression of intestinal tumorigenesis was also observed in APCMin/+ 
mice following celecoxib treatment as well as the genetic disruption of Cox-2.127,128 
Moreover, the genetic ablation of hydroxyprostaglandin dehydrogenase-15 (15-
PGDH), a prostaglandin-degrading enzyme regulating endogenous PGE2 levels, 
markedly increased colon tumorigenesis in APCMin/+ mice and a carcinogen-induced 
model.129 As such, there exists a large body of evidence converging on the critical 
contribution of Cox-2/PGE2 pathway in the neoplastic progression of CRC.   
 
During chronic inflammation or the initiation of epithelial tumors, Cox-2 induced PGE2 
biosynthesis can be triggered in transformed or normal epithelial cells as well as tissue-
resident immune cells.114 In the context of CRC, Cox-2/PGE2 signaling is known to 
promote colon carcinogenesis through a variety of mechanisms. Besides its 
interaction with the Ras-MAPK cascade, the Cox-2/PGE2 pathway can also stimulate 
colorectal tumor growth through activation of the epidermal growth factor receptor 
(EGFR) and Wnt/β-catenin pathways.130,131 In addition, Cox-2 derived PGE2 can 
promote the survival of colorectal cancer cells via activation of apoptosis inhibitory 
pathways such as PI3K/AKT signaling, as well as inducing the expression of anti-
apoptotic genes including Bcl-2.132 The overexpression of Cox-2 in colon cancer cells 
is also associated with angiogenesis-promoting effects such as the increased production 
of angiogenic factors,133 consistent with the role of Cox-2 in promoting CRC 
progression through stimulation of tumor vascularization. Moreover, Cox-2 and PGE2 
have been reported to enhance the metastatic potential of colorectal tumor cells through 
increasing cancer cell migration and invasiveness.134,135 More recently, a novel role for 
PGE2 in the promotion of intestinal tumor growth and progression was uncovered, 
whereby PGE2 was found to silence certain tumor suppressor and DNA repair genes 
via regulation of DNA methylation.136  
 
In spite of its pro-carcinogenic functions, Cox-2-dependent PGE2 is also a critical 
mediator of epithelial repair responses during intestinal injury. This is due to its pro-
proliferative and anti-apoptotic effects on intestinal epithelial cells as highlighted 
earlier. This mucosal healing role of PGE2 was addressed in at least three studies (one 
of which was discussed in the previous section), whereby LPS administration or the 
TLR4- and MyD88- dependent pathways were found to be crucial for the induction of 
epithelial restitution following intestinal injury.107,137,138 Notably, the decreased 
epithelial proliferation and increased apoptosis observed in Cox-2-, TLR4- and 
MyD88- deficient mice treated with DSS was rescued by exogenous PGE2 
administration.107,138  However, while Cox-2-dependent PGE2 signaling was found to 
be important for the induction of epithelial regeneration following acute colitis, the 
induction of Cox-2 appeared to promote the development of CAC during chronic 
intestinal inflammation.109 Taken together, these studies reveal that although the 
stimulatory effects of Cox-2/PGE2 signaling on epithelial proliferation is critical for the 
maintenance of a healthy intestinal epithelial barrier, they can also be diverted into 
tumor promoting pathways in a genetically predisposed environment.  
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2 AIMS OF THESIS 
 
The main objective of this thesis is to examine the role of gut microflora and 
inflammation in driving intestinal tumorigenesis and the regulation of gut homeostasis.  
 
 
2.1 SPECIFIC AIMS 
To achieve this, we investigated the role of commensal microflora and explored the 
contribution of underlying inflammatory mediators in the tumor progression of 
APCMin/+ mice (Paper I). We then ventured into the signaling mechanisms of luminal 
microbes and focused on the Toll-like receptor 4 (TLR4) pathway, a major component 
of microbial signaling mediated via gram negative bacteria. Here, we examined the role 
of constitutive epithelial TLR4 signaling in the regulation of intestinal homeostasis and 
APCMin/+-driven tumorigenesis (Paper II). We further investigated the host mechanisms 
driving intestinal inflammation during pathogenic bacterial infection (Paper III). 
Finally, we attempted to understand the transcriptional regulation of inflammatory and 
oncogenic responses through evaluation of the role of bromodomain-containing protein 
4 (BRD4) in transcriptional elongation (Paper IV). 
 
 
2.2 SIGNIFICANCE OF STUDY 
The primary significance of all four studies is the eventual hope to: 
 
 Identify critical inflammatory cascades and mediators driving the disease 
progression of human CRC.  
 Enhance our understanding of how pathogenic microbes interact with the host 
during enteric infections. 
 Provide targets for the therapeutic intervention of intestinal inflammation and 
cancer through understanding of the signalling mechanisms by which gut 
microbes regulate mucosal inflammation, tumor growth and apoptosis.   
 Selectively limit the activation of pro-inflammatory or tumor-promoting 
responses through targeting histone modifications and/or transcriptional co-
regulators. 
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3 METHODOLOGY 
 
In this section, I describe some of the unique systems which we developed during the 
course of my PhD studies while majority of the well-established scientific methods 
used in my work are elaborated in the constituent papers.  
 
 
3.1 PRIMARY CULTURE OF SPLENIC MACROPHAGES, COLONIC 
EPITHELIAL CELLS AND TUMORS  
In an attempt to understand the underlying mechanisms governing inflammation-
associated APCMin/+ tumorigenesis, we analyzed for two major inflammatory pathways 
connected to CRC – STAT3 and c-Jun activation, using a series of ex vivo culture 
assays of purified splenic macrophages, colonic epithelial cells and intestinal tumors 
from APCMin/+ mice. 
 
3.1.1 Purification of splenic macrophages 
Although the most relevant site of analysis for the role of myeloid cells would be from 
the tumor microenvironment itself, we have attempted and recognized the technical 
difficulty in obtaining sufficient purified CD11b+ cells from colonic tumors for 
different treatment groups. This is due to the much lower incidence of colonic tumors 
as compared to small intestinal tumors in APCMin/+ mice. Moreover, the long digestion 
and purification times of several pooled tumors may have contributed to the increased 
cell death or change in phenotype of this population. As such, we chose to purify 
mature macrophages from the spleens of APCMin/+ mice which developed colonic 
tumors instead, based on the assumption that they would be mobilized to the tumor site 
eventually.     
 
Spleens from colon tumor-bearing APCMin/+ mice were dissociated mechanically into 
single cell suspensions in RPMI-1640 medium, using blunt-end forceps. The cell 
suspensions were then washed with PBS before incubation with erythrocyte lysis buffer 
(155mM NH4Cl, 12mM NaHCO3, and 0.1mM EDTA) for 5-10min at RT to remove 
erythrocytes. Cells were subsequently washed with ice-cold PBS, passed through 45μm 
cell strainers and counted. For isolation of CD11b+ macrophages, splenocytes were 
resuspended in 90μl of buffer (cold PBS containing 0.5% BSA and 5mM EDTA to 
prevent cell clumping) per 107 cells and 10μl of CD11b-specific microbeads (Miltenyi 
Biotec) were added. Incubation with gentle rotation was performed for 30min at 4°C 
and cell purification was conducted using MS columns (Miltenyi Biotec) in accordance 
with manufacturer’s recommendations. 
   
After purification, splenic CD11b+ cells were incubated in RPMI-1640 medium 
(supplemented with 1% FBS and antibiotics) at 37ºC for 30min to allow them to adapt 
to culture conditions and minimize non-specific effects, before stimulation with EPO 
(600 U/ml) for 1h. Reduced serum conditions were used to increase the contact of 
added stimulants with their receptors on macrophages and minimize any possible 
interaction of stimulants with serum components. Even though we detected an 
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induction of STAT3 activation in the macrophages following 1h of erythropoietin 
(EPO) stimulation (Paper I, Figure 5Bi), we decided to collect conditioned media after 
24h of stimulation in the bid to maximize the pool of secreted cytokines, chemokines or 
growth factors in the conditioned media, without causing cell death in the myeloid 
cells. Moreover, the macrophages retained elevated mRNA expression levels of STAT3 
target genes following 24h of stimulation (Paper I, Figure 5Bii), thereby reaffirming 
suitability of our chosen treatment time point. This conditioned media was used for 
subsequent proliferation assays involving the CT26 murine colon carcinoma cell line.  
 
3.1.2 Ex vivo treatment of colonic epithelial cells and tumors 
As we observed an induction of c-Jun phosphorylation in the CT26 epithelial cell line 
following incubation with conditioned medium of LPS-treated macrophages, we were 
also interested to understand if gut microflora has a direct effect on intestinal epithelial 
cells. In an attempt to mimic the in vivo situation as much as possible, we used LPS as a 
major gut microbiotal component to treat primary colonic epithelial cells ex vivo, from 
GF mice as they have not been colonized with any microorganisms since birth.  
 
Colons from these mice were cut longitudinally, washed and minced into 5mm 
segments. The tissues were then digested with dispase I (1mg/ml) at 37ºC for 90min. 
Mild digestion methods such as using dispase I with gentle mechanical shaking were 
chosen to obtain live colonic epithelial cells with as few contaminating lamina propria 
cells as possible. Following digestion, tissues were flushed gently several times with 
DMEM medium to release cells and crypts. The cells were then plated at a density of 
~1.5x106 cells per well in 24-well plates that were coated with a 1:1 solution of 
DMEM: matrigel as a form of substratum for the primary epithelial cells to attach to. 
Subsequently, the colonic epithelial cells were allowed to settle for 30min before LPS 
exposure for 30min.   
 
In order to correlate our tumor counts data from EPO treated APCMin/+ mice with levels 
of STAT3 phosphorylation observed in colonic tumors of untreated APCMin/+ mice, we 
decided to perform ex vivo treatment assays of colonic tumors isolated from APCMin/+ 
mice. As better ex vivo culture techniques of primary intestinal tumors were not 
available at that time, we decided to adopt a similar method for our tumor cultures as 
per primary colonic epithelial cells. Although we were able to obtain an induction of 
STAT3 phosphorylation in pooled colonic tumors with EPO treatment and that was 
consistent for at least 3 experimental sets, it was a technical challenge to obtain similar 
levels of fold induction possibly owing to the variable basal state of tumors from 
different APCMin/+ mice of varying health statuses. As such, we acknowledge that 
improved methods for the long term expansion of both colonic epithelia and tumors for 
human tissues are now published139 and may be more appropriate for our ex vivo 
stimulation assays if such techniques can be optimized for mouse colonic tissues as 
well. 
 
 
3.2 INTESTINAL CRYPT-VILLUS ORGANOID CULTURE SYSTEM 
The isolation of intestinal crypts from murine small intestines for the long-term culture 
and expansion of crypt-villus organoids ex vivo was established by the Hans Clevers 
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group.140 It is a novel approach to obtain long-term cultures of primary intestinal crypts 
that can expand and differentiate to form all other lineages of the intestinal epithelium. 
We have adapted this crypt isolation procedure in Paper II to examine how constitutive 
epithelial TLR4 activation regulated intestinal epithelial cell proliferation and 
differentiation, without interference from the underlying mesenchyme.  
 
Mouse small intestines were opened longitudinally, washed thrice in PBS and cut into 
1-3mm segments. Tissues were then incubated with 2mM EDTA/PBS at 4°C for 
30min, before vigorous resuspension with the pipet for 40 times. Following 3min of 
tissue sedimentation, the supernatant was removed and the gut pieces were washed 
twice with ice-cold PBS. This resuspension step was subsequently repeated twice using 
fresh ice-cold EDTA/PBS and the supernatant collected at the last resuspension (i.e. the 
crypts-enriched fraction) was plated with 50μl of matrigel, at a density of 6x103 crypts 
per well in 48-well plates. The plates were then incubated at 37ºC for 30min before 
adding culture medium supplemented with growth factors and additives, in accordance 
with the published protocol.140  
 
3.2.1 Sorting of Paneth cells  
For the purification of Paneth cells, primary murine intestinal crypts were purified as 
described above and dissociated in culture medium containing 0.5X trypsin for 40min 
in a 37ºC shaking incubator. Cells were resuspended by pipetting at 10min intervals to 
facilitate dissociation into single cells. The trypsin was then neutralized with medium 
containing 20% FBS before passing the cell suspension through a 40μm cell strainer. 
Cells were subsequently resuspended in PBS/2% FBS and incubated with anti-CD24 
antibody (1μg antibody per million cells) (BD Pharmingen) for 50min on ice. 
Following primary antibody incubation, cells were washed with ice-cold PBS/2% FBS 
and stained with Alexa-fluor488 goat anti-rat IgG (Invitrogen) (1μl antibody per 300μl 
cell suspension) for 30min at 4ºC. Stained cells were then washed once and 
counterstained with DAPI (4',6-diamidino-2-phenylindole) before sorting of viable 
CD24hi/SSChi (side scatter) Paneth cells by flow cytometry, in accordance with the 
parameters highlighted by Hans Clevers group.141  
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4 RESULTS AND DISCUSSION 
 
This thesis consists of four papers which represent a concerted effort to understand how 
host-microbe interactions regulate intestinal homeostasis, inflammation and 
tumorigenesis, as well as the significance of histone modification patterns and 
chromatin-associated proteins in the regulation of gene expression. 
 
 
4.1 PAPER I: GUT MICROBIOTA ACCELERATE TUMOR GROWTH VIA 
C-JUN AND STAT3 PHOSPHORYLATION IN APCMIN/+ MICE 
 
In our investigation of the role of gut microflora in the tumorigenesis of APCMin/+ mice, 
we found that APCMin/+ mice which have not been exposed to microflora since birth i.e. 
GF APCMin/+ displayed a remarkable down-regulation of intestinal tumor incidence as 
compared to their age-matched specific pathogen free (SPF) counterparts (Figure 1). 
Moreover, we also observed a significant reduction of intestinal tumor load in SPF 
APCMin/+ carrying a myeloid-specific deletion in IKKβ (Figure S5). These two 
observations support the tumor promoting role of commensal microbiota in a genetic 
susceptibility model, which most likely involves the activation of myeloid cells from 
lamina propria. We thus hypothesized that inflammation triggered by the invasion of 
microflora into lamina propria, following disruption of the epithelial lining during the 
formation of intestinal lesions, enhanced the tumor progression of APCMin/+ mice. 
 
As such, we further addressed the inflammatory pathways and cellular mediators that 
may be driving APCMin/+ tumorigenesis through in-depth characterization of the 
intestinal tumors and various types of immune cells infiltrating these tumors, as well as 
a variety of ex-vivo treatment assays of primary tumors and myeloid cells. We found a 
distinct pro-inflammatory status in APCMin/+ colonic tumors as compared to small 
intestinal tumors (Figure 2B-D), which correlated with the histological verification of 
epithelial lining disruption in regions surrounding colonic lesions but not small 
intestinal lesions (Figure 2A). This was also consistent with a significantly higher 
amount of infiltrating CD11b+ and GR1+ myeloid cells in colonic tumors (Figure S3-
4), strongly suggesting the involvement of TAMs in the perpetuation of tumor-
promoting inflammation as reported in various CAC models.46,63  
 
Moreover, the significantly increased levels of phosphorylated c-Jun and p-STAT3 
(Tyr-705) in colonic tumors (Figure 2C-D) demonstrated the up-regulation of two well 
established oncogenic pathways - JNK-c-Jun/AP-1 and JAK/STAT3 signaling, during 
APCMin/+colonic tumorigenesis. Their critical involvement in mediating tumor cell 
proliferation and survival was further illustrated in our ex vivo stimulation assays of 
primary APCMin/+ tumors and CD11b+ macrophages (Figure 5A-B and 6A-B). Notably, 
JNK-mediated c-Jun phosphorylation, which has been implicated in mediating 
APCMin/+ intestinal tumorigenesis via cooperative interaction of the AP-1 complex with 
TCF4 and β-catenin,35 could be induced in primary colonic epithelial cells by a major 
microbiotal component of gram-negative bacteria - lipopolysaccharide (LPS) (Figure 
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6C) and was also necessary for the induction of epithelial cell proliferation (Figure 6A-
B). 
 
In addition to the direct proliferative effect of gut microbiota on epithelial cells during 
tumorigenesis, soluble factors produced by activated myeloid cells infiltrating the 
colonic tumors also have a significant tumor-promoting role as suggested by our 
findings (Figure S5). One crucial observation in our study was the detection of high 
levels of activated STAT3 in tumor-associated macrophages of APCMin/+ colonic 
adenomas (Figure 2E and S7). Importantly, erythropoietin (EPO) which triggered colon 
tumorigenesis in APCMin/+ mice (Figure 4) was also found to induce STAT3 activation 
in APCMin/+ colonic tumors and splenic macrophages ex vivo (Figure 5A-B). The 
critical connection between JAK/STAT3 signaling and APCMin/+ tumorigenesis was 
further elucidated in our study through the administration of curcumin, a known 
STAT3 inhibitor,142 in APCMin/+ mice. In particular, we found that the short-term 
treatment of APCMin/+ mice with curcumin, which has previously been shown to reduce 
intestinal tumorigenesis,143 could induce the down-regulation of p-STAT3 (Tyr-705) in 
their colonic tumors (Figure 5C). As STAT3 phosphorylation has been associated with 
tumor-promoting functions such as the suppression of anti-tumor immunity in myeloid 
cells53 and stimulation of intestinal epithelial cell proliferation and survival,62,63 our 
findings thereby establish the causal role of STAT3 activation, most notably in tumor-
associated myeloid cells, in APCMin/+ colon tumorigenesis. 
 
Furthermore, the finding that EPO administration can promote colon tumorigenesis in 
APCMin/+ mice (Figure 4) has important clinical implications as EPO is traditionally 
used to treat anemia in cancer patients and is also popular amongst athletes as a 
performance enhancing drug. EPO can trigger JAK-mediated phosphorylation of all 
STATs through engagement with the EPO receptor (EPO-R),144 which is known to be 
expressed on erythrocyte precursors and certain tumor cells.145,146 Although EPO 
signaling via EPO-R activation is widely recognized to induce erythropoiesis in 
erythroid progenitor cells via JAK2/STAT5 signaling,146 EPO has also been reported to 
act directly on macrophages, enhancing their pro-inflammatory activity and function.147 
Meanwhile, our finding that EPO can induce STAT3 activation in macrophages (Figure 
5B) reaffirms that EPO-R may be found on myeloid cells as well and that its activation 
can mitigate other erythropoiesis-independent functions in non-erythroid progenitor 
cells. As EPO has also been demonstrated to exert tumor-promoting effects such as the 
paracrine stimulation of tumor angiogenesis,148 our findings therefore provide further 
understanding to the multiple tumor-promoting mechanisms of EPO.     
 
In conclusion, our data from this study illustrates the active role of gut microflora in 
promoting intestinal tumorigenesis during microbial dysbiosis-triggering events, such 
as the loss of epithelial barrier integrity. Thus, an aberrant mucosal barrier in the 
APCMin/+ mouse model propagates a chronic inflammatory state in the gut which drives 
enhanced tumor growth and progression. This vicious feed forward cycle of augmented 
intestinal lining disruption and tumor-promoting inflammation is mediated by at least 
two distinct pathways – JAK/STAT3 activation in myeloid cells and JNK-dependent c-
Jun phosphorylation in intestinal epithelial cells. Henceforth, targeting the two 
pathways sequentially or in combination, in the specific tissue compartments, may 
represent an effective therapeutic strategy for CRC patients harboring APC mutations. 
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4.2 PAPER II: CONSTITUTIVE TLR4 SIGNALING IN INTESTINAL 
EPITHELIUM REDUCES TUMOR LOAD BY INCREASING 
APOPTOSIS IN APCMIN/+ MICE 
 
After establishing the critical role of gut microbiota in fuelling inflammation-driven 
intestinal tumorigenesis in APCMin/+ mice, we proceeded further to examine the host-
microbial signalling pathways involved in the regulation of intestinal tumor growth and 
development. One major class of PRRs involved in microbial recognition and 
signalling through the host is TLRs, which play a critical role in regulating intestinal 
homeostasis and tumorigenesis as discussed in section 1.5.2. In the earlier described 
study by Medzhitov’s group, the genetic ablation of MyD88, a major signalling adaptor 
downstream of TLRs, resulted in a dramatic reduction in the intestinal tumor burden of 
APCMin/+ mice.112 This finding resonated strongly with our data in the first study and 
thus led us to focus our attention on the TLR4 pathway, a major component of host-
microbe interactions mediated by gram negative bacteria. 
 
As we observed in the previous study that LPS, a known activator of TLR4 signaling, 
could stimulate epithelial cell proliferation (Paper I, Figure 6B), we thus hypothesized 
that constitutive TLR4 activation in the gut would stimulate tumor growth in APCMin/+ 
mice. As such, we generated transgenic mice expressing constitutively active TLR4 
(CD4-TLR4) specifically in the intestinal epithelium and crossed them with APCMin/+ 
mice. Unexpectedly, we found that APCMin/+ mice expressing intestinal epithelial cell-
specific CD4-TLR4 displayed significantly reduced tumor load and size, relative to 
age-matched, wild-type APCMin/+ mice (Figure 1). This observed suppression of 
spontaneous tumorigenesis in a genetically susceptible model was in stark contrast to a 
CAC model, whereby constitutive TLR4 signaling in the intestinal epithelium 
augmented inflammatory responses to colitis, which promoted carcinogen-induced 
tumorigenesis in an AOM/DSS treatment regimen.111 The two apparently disparate 
facades of constitutive TLR4 activation in the regulation of intestinal tumorigenesis 
highlight the context dependent manner of this control, thereby prompting us to further 
probe the underlying mechanism in our CD4-TLR4-APCMin/+ mice. 
 
Interestingly, CD4-TLR4 transgenic mice exhibited a higher proliferative status in the 
intestinal epithelium, as illustrated by increased nuclear Ki-67 staining in epithelial 
cells residing above crypt bases (Figure 2A) as well as ex vivo intestinal crypt-villus 
organoids (Figure 3B). These findings were consistent with the data from our earlier 
study. Furthermore, persistent epithelial TLR4 activation had a significant impact on 
the functions of all secretory cell lineages, namely Paneth cells, goblet cells and 
enteroendocrine cells (Figure 3C). Notably, constitutive epithelial TLR4 stimulation 
enhanced Paneth cell activity, which was consistent with the increased expression of 
markers for Paneth cell functions and intestinal stem cells (Figure 3C). These 
observations correlated well with the increased proliferative potential of CD4-TLR4 
organoids (Figure 3) and extend support to the current notion that Paneth cells provide 
essential niche signals for the survival and expansion of intestinal stem cells.141 
Importantly, the findings reveal that long-term TLR4 signaling in the intestinal 
epithelium can impact on both the stem cell and differentiated epithelial lineages, 
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which may have major functional consequences on intestinal homeostasis and 
regenerative responses. 
 
Hence, we were intrigued by the reduced tumor burden of CD4-TLR4 expressing 
APCMin/+ mice despite the increased proliferative capacity of the intestinal epithelium 
and searched for alternative pathways of TLR4 activation that can provide a plausible 
explanation for this phenomenon. Surprisingly, the persistent activation of TLR4 led to 
a down-regulation of Cox-2 in both CD4-TLR4 expressing intestinal organoids and 
tumors (Figure 3C and 4B). This down-regulation of Cox-2 expression was inversely 
correlated with levels of transgene expression as well as the expression of pro-apoptotic 
markers (Figure 4A and C), suggesting of a modulation of the pro-survival functions of 
Cox-2 by constitutive TLR4 signaling. Although we were unable to identify the precise 
regulator of Cox-2 in this study, we found that interferon β (IFNβ), a direct target of the 
TLR4 pathway was significantly up-regulated in CD4-TLR4 expressing tumors (Figure 
4B). This cytokine, popularly known for its host defense function against microbial 
pathogens and tumor cells, has been previously demonstrated to inhibit the transcription 
of Cox-2 in intestinal epithelial cells.149 Of note, the production of IFNβ by TLR4 
activated tumors was also implicated to be critical in mediating anti-tumoral 
immunity.150  
 
Indeed, the down-regulation of Cox-2 was consistent with an elevated apoptotic status 
in CD4-TLR4-APCMin/+ tumors as compared to tumors from wild-type APCMin/+ mice. 
This was elegantly visualized in vivo using the FAM-FLIVO apoptosis assay and 
verified by the enhanced protein levels of cleaved caspase 3 in CD4-TLR4-APCMin/+ 
tumors (Figure 5B-D). While markers of tumor cell proliferation and autophagy remain 
unperturbed (Figure S6), the increased apoptosis in tumors of transgenic APCMin/+ mice 
provided a plausible mechanism for their reduced tumor incidence and size. This was 
also consistent with studies demonstrating the amelioration of intestinal tumor burden 
in FAP patients and APCMin/+ mice treated with Cox-2 inhibitors.126,151 Furthermore, 
evidence of the improved efficacy of a treatment regimen involving Cox-2 inhibitor 
and IFNβ, in reducing the survival of xenograft tumors via induction of apoptosis,152 
lend further support to our data. Interestingly, the normal intestinal mucosa of CD4-
TLR4 mice displayed similar levels of apoptotic cells as wild-type mice (Figure S7), 
implying that the enhanced apoptosis detected is only unique to a genetically 
predisposed setting.   
 
Thus, our findings reveal a fine equilibrium between proliferation and programmed cell 
death in the intestinal epithelium that is regulated by microbial signaling. In particular, 
persistent TLR4 activation in the gut stimulates both epithelial cell proliferation and the 
functions of all secretory cell lineages. While normal homeostatic mechanisms are in 
place to prevent aberrant crypt-villus outgrowth, as depicted by the normal intestinal 
morphology of CD4-TLR4 mice (Figure S1D), our data show that in a genetically 
susceptible environment such as in the APCMin/+ background, a higher extent of 
apoptosis ensues, resulting in a suppression of spontaneous tumorigenesis. Moreover, 
we further related our observations to the intriguing down-regulation of a critical 
survival factor, Cox-2, which is known to mediate tumor promoting effects (as 
discussed in section 1.6) and is frequently correlated with a poorer prognosis of CRC 
patients. Although Cox-2 expression has been shown to be induced in colorectal cancer 
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cells by short-term, acute stimulation of TLR4,138 our data indicates that the persistent 
activation of TLR4 in intestinal epithelial cells results in the down-regulation of Cox-2 
instead.    
 
While additional bystander mechanisms may be triggered during constitutive TLR4 
activation, that in turn regulate tumor growth and progression, we have so far identified 
IFNβ as a potential inducer of anti-tumoral immunity.  This is an interesting aspect of 
microbial signaling that is not well understood till date. Moreover, the increased 
expression of a TLR4-inducible RNase and known immune response modifier - 
Zc3h12a,153,154 in CD4-TLR4-expressing tumors (Figure S8C) further reinforces this 
concept. It remains to be determined whether Zc3h12a can also modulate Cox-2 
expression. As such, although our findings from the previous study as well as 
Medzhitov's study112 demonstrate the active role of host-microbial interactions in tumor 
promotion, the constitutive activation of a major aspect of microbial signaling resulted 
in tumor inhibition instead. Our findings thereby reveal the complex regulation of 
TLR4 signaling, which can trigger both MyD88- dependent and -independent 
mechanisms, as well as apoptotic pathways during constitutive activation in a 
genetically predisposed environment. This intriguing facade of host-microbe crosstalk 
adds on to the complexity highlighted in section 1.5.2 and has important functional 
implications in the use of microbial ligands or long-term antibiotics administration in 
the treatment of various gastrointestinal health ailments.  
 
 
4.3 PAPER III: ABSENCE OF INTESTINAL PPARG AGGRAVATES 
ACUTE INFECTIOUS COLITIS IN MICE THROUGH A LIPOCALIN-2 
DEPENDENT PATHWAY 
 
The findings from our first two papers have provided an insight of how the complex 
interaction between the commensal microbiota and host can lead to diverse outcomes in 
intestinal tumorigenesis. Moving forward, we were interested to further investigate how 
pathogenic microbes interact with the host innate immune system to impact on 
intestinal homeostasis and mucosal defense. Thus in this study, we used a bacterial 
pathogen which causes enterocolitis -Salmonella enterica serotype Typhimurium in our 
model of infectious colitis to examine the host defense mechanisms during intestinal 
microbial infection. We decided to focus our attention on the nuclear receptor -
peroxisome proliferator-activated receptor γ (PPARγ) because of its well established 
role in the regulation of inflammation and maintenance of gut homeostasis.  
 
Belonging to the superfamily of ligand-dependent transcription factors, PPARγ is 
highly expressed in adipose and colonic tissues.155 Its activation upon ligand 
recognition entails the heterodimerization with retinoid X receptor α (RXRα) in the 
nucleus, thereby facilitating the transcriptional regulation of specific genes via binding 
of the heterodimer to PPARγ response elements (PPREs).156 In addition to its role in 
regulating adipocyte differentiation and carbohydrate metabolism,155 PPARγ is well 
recognized as a critical immunomodulatory factor through its ability to down-regulate 
the expression of inflammatory cytokines, antagonize the activities of AP-1, STAT and 
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NF-κB, and polarize immune cell functions towards an anti-inflammatory 
phenotype.157,158 Notably, PPARγ and its agonists have been implicated as crucial 
mediators of intestinal homeostasis and antimicrobial immunity, as well as potential 
therapeutic agents for the treatment of colitis.159-162 Moreover, its strategic involvement 
in the host-microbe crosstalk, traversing between microflora-driven signals and the 
regulation of host inflammatory responses,163,164 further fueled our interest in its 
regulation during S. Typhimurium induced colitis. 
 
In our investigation, we observed that S. Typhimurium infection of mice pretreated 
with streptomycin resulted in the down-regulation of PPARγ expression in the colon 
after 24h (Figure 1A-C), suggesting of a perturbation in the homeostasis of the 
intestinal tract during infectious colitis. Consistently, mice carrying an intestinal 
epithelial cell-specific deletion of PPARγ (PPARγVillinCre+) displayed a more 
aggravated colitis than WT mice during S. Typhimurium infection (Figures 1D-E and 
2). This increased severity of colitis in PPARγVillinCre+ mice and the concomitant 
induction of NF-κB and AP-1 activities in colon (Figures 3A-B, S2 and S3) 
corresponded with an elevated expression of inflammatory cytokines - TNF-α, IL-6, 
IL-17 and IL-22 (Figure 3C-F). Interestingly, the induction of IL-17 and IL-22 during 
infection correlated with an innate T helper type 17 (iTH17) response, which was 
recently documented to be crucial for host defense against enteric pathogens including 
S. Typhimurium.165 In particular, IL-22 was reported to stimulate the luminal release of 
antimicrobials such as regenerating islet-derived 3 gamma (Reg3γ) and lipocalin-2 
(Lcn2) by epithelial cells.166,167 Accordingly, the two antimicrobials were similarly 
induced during S. Typhimurium infection, with a corresponding pattern of augmented 
expression observed in mice lacking gut epithelial PPARγ as compared to WT mice 
(Figure 4). These findings therefore depict the significant role of epithelial PPARγ in 
the regulation of intestinal homeostasis and innate immune responses during exposure 
to bacterial pathogens. 
 
We then sought to further examine the consequences of the heightened inflammatory 
and antimicrobial responses in infected PPARγVillinCre+ mice during disease 
pathogenesis. To our surprise, we found an elevated activity of both precursor and 
cleaved forms of matrix metalloproteinase 9 (proMMP-9 and MMP-9 respectively), 
which correlated with enhanced levels of Lcn2 bound proMMP-9 (proMMP-9/Lcn2) 
(Figure 5A-B). This finding disclosed a previously unexplored role of Lcn2 in 
promoting the stability of MMP-9 during infectious colitis, which can potentially lead 
to more severe tissue degradation arising from the increased enzymatic activity of 
MMP-9. Consistent with this notion, lipocalin-2 knockout mice (Lcn2-/-) displayed a 
marked protection from epithelial denudation and tissue damage during S. 
Typhimurium infection (Figure 6), which corresponded to the reduced secretion and 
activity of proMMP-9 and MMP-9 in the intestinal milieu (Figure 7A-D) as compared 
to WT or PPARγVillinCre+ mice (Figure 5). Taken together, our results thereby 
illustrate how enteric pathogens such as S. Typhimurium can regulate and exploit the 
host innate immune and mucosal defense (antimicrobial) mechanisms to create an 
inflammatory environment that favors its survival and colonization in the host. 
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4.4 PAPER IV: BROMODOMAIN-CONTAINING-PROTEIN 4 (BRD4) 
REGULATES RNA POLYMERASE II SERINE 2 PHOSPHORYLATION 
IN HUMAN CD4+ T CELLS 
 
In our previous three studies, we have demonstrated that changes in the expression of 
specific genes associated with cell proliferation, apoptosis, immune cell functions, and 
antimicrobial responses are important determinants of tumor survival and progression, 
inflammation as well as host responses to bacterial pathogens. One critical regulatory 
platform controlling host-microbial, inflammatory and/or oncogenic transcriptional 
responses is the post-translational modification of histones. These covalent 
modifications occur at the amino-terminal tails of histones and include acetylation, 
methylation, phosphorylation, ubiquitination and ribosylation, all of which are 
dynamically mediated by histone modifying enzymes.168,169 The remarkable diversity 
of histone marks and their combinatorial complexity have led many investigators to 
favor the view that distinct histone modification patterns encode a ‘language’ that is 
read by other proteins to generate unique biological outcomes.168 This concept was thus 
coined the ‘histone code hypothesis’168,170 and further proposed to impact on 
chromatin-related processes, thereby leading to distinct cell fate decisions and the 
development of both normal and pathological states.171  
 
Indeed, the post-translational modification of histones impacts significantly on the 
regulation of gene expression through its ability to modulate chromatin structure and 
the recruitment of transcriptional regulators. Since the ‘histone code hypothesis’ was 
posited, emerging literature have revealed how alterations in covalent histone 
modifications and dysregulation in chromatin regulators are closely linked to the 
development and progression of cancer.169,172,173 Moreover, chromatin remodeling 
processes and the transcriptional mediators that bind to specific chromatin 
modifications have also been implicated in the selective induction of inflammatory 
gene expression programs.174-176 Thus in this study, we initially sought to understand 
the underlying epigenetic events regulating the transcriptional control of inflammatory 
or oncogenic responses globally. 
 
We decided to focus our attention on a bromodomain-containing protein, BRD4, a 
member of the BET (bromodomains and extraterminal) family that recognizes 
acetylated lysine residues on histone tails.177 Originally discovered as a ubiquitously 
expressed nuclear protein that binds to mitotic chromosomes, BRD4 was shown to 
mark select genes for transcriptional memory and regulate cell-cycle progression.178 
This double bromodomain-containing protein was later found to be critical for the 
recruitment of transcriptionally active P-TEFb (positive transcription elongation factor) 
to promoter, leading to stimulation of RNA polymerase II (Pol II)-dependent gene 
transcription.179 Notably, BRD4 was identified as a novel co-activator of NF-κB 
through interaction with an acetylated lysine of RelA, further enhancing the 
transcription of NF-κB-dependent inflammatory genes via P-TEFb recruitment.180 In 
addition, BRD4 recruitment to promoters was found to be critical for the transcription 
of genes involved in cell cycle progression181 and this chromatin adaptor was also 
implicated in oncogenesis.182 Taking into account its ability to bind acetylated 
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chromatin and significant role in transcription co-activation, BRD4 thus represented an 
interesting platform for us to examine the epigenetic mechanisms leading to 
inflammation as well as cancer. 
 
In our genome-wide analysis of BRD4 binding sites using chromatin 
immunoprecipitation sequencing (ChIP-Seq), we found that BRD4 was predominantly 
associated with actively transcribed genes in human CD4+ T cells and its recruitment 
was positively correlated with levels of gene expression (Figure 1). Consistent with its 
co-regulatory role in transcriptional elongation,179,180 the global distribution of BRD4 
coincided mostly with known promoter and enhancer regions, with over 50% of 
binding sites occurring  at intergenic and intragenic regions (Figure 2). Interestingly, 
BRD4 binding sites co-localized with that of Pol II and Ser2-phosphorylated Pol II (Pol 
II Ser2) at the promoters and enhancers of genes marked by active histone marks 
(Figure 3 and Figure S3). These observations therefore implicate the significant 
contribution of BRD4 in transcriptional elongation at a genome-wide level, which is 
potentially mediated through its recruitment of P-TEFb to Pol II bound sites. 
 
As the signal-dependent recruitment of P-TEFb/BRD4 complex in the induction of 
gene-specific transcription elongation has been demonstrated previously to be 
dependent on the crosstalk with acetylated histones,183,184 we thus examined the 
interaction of BRD4 with various acetylated histone marks. Through integration of 
global BRD4 binding sites with published databases of genome-wide acetylated histone 
sites, we found that majority of BRD4 binding sites was associated with histone 4 (H4) 
acetylated on lysine residues 5 and 8 (H4K5ac and H4K8ac respectively) (Figure 4). 
These interactions were further verified in vitro via histone peptide binding assays 
(Figure 4F and H), indicating that BRD4 can be recruited to promoters and enhancers 
through binding with acetylated histones. We thus proceeded further to assess the 
significance of this recruitment in the transcription of BRD4-bound genes by disrupting 
the binding of BRD4 to acetylated histones using a known BET inhibitor, JQ1.185 As 
expected, JQ1 treatment resulted in the global reduction of both BRD4 and Pol II Ser2 
gene occupancy, with a corresponding decrease in the expression of BRD4-bound 
lineage-specific genes in human CD4+ T cells (Figure 6). In addition, an enrichment of 
P-TEFb binding was also identified in a subset of enhancers where BRD4 and Pol II 
Ser2 were co-localized (Figure 8C-E) and the direct interaction of P-TEFb and BRD4 
was verified in human T cells (Figure 8B). Thus taken together, our ChIP-seq data 
suggest the positive regulation of BRD4 in Pol II Ser2-mediated transcriptional 
elongation through P-TEFb recruitment at specific histone modifications, which is 
likely to drive the transcription of genes in a lineage-specific or signal-dependent 
manner.  
 
Through the study of BRD4 in transcriptional regulation, we provide evidence for the 
significant role of histone modifications and chromatin-binding proteins in the 
regulation of specific gene expression. The dynamic interplay of a variety of histone 
modifiers as well as the ability of specific histone marks to modulate gene expression 
through interaction with transcriptional co-regulators allows for a gene to be expressed 
or silenced according to its function. This selective regulation of gene expression is not 
only important for the induction of an inflammatory response, but also the timely 
resolution of acute inflammation to restrict excessive tissue damage. The recent 
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characterization of BRD4 as a key determinant of various malignancies and 
inflammatory diseases186-190 attests further to the significance of the ‘histone code’ and 
highlights the future promise of cancer epigenetic therapy via selective targeting of 
chromatin-associated regulators or chromatin remodeling.  
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5 CONCLUDING REMARKS AND PERSPECTIVES 
 
The gut microbiota isn’t simply a repository of microorganisms residing quiescently in 
our gastrointestinal tracts. These microbes, popularly referred to as ‘our commensals’, 
participate actively in several important biological processes that shape our immune 
system, intestinal homeostatic functions and development, as well as metabolism. As 
these microbes depend directly on their host for shelter and raw materials, it seems 
pretty intuitive that they would protect their host’s well-being in order to ensure their 
own survival. However, this symbiotic relationship can be easily disrupted in the wake 
of physical lesions, pathogenic infections or deregulated inflammatory responses in the 
gut, often arising from certain genetic susceptibility event(s), and the commensals 
become a major threat to the host’s health instead. Indeed, as we have learnt from past 
studies, microbial dysbiosis can trigger a cascade of events leading to various 
pathological conditions including obesity, diabetes, IBD and cancer. Therefore, 
understanding how the microbiota signals through the host, as well as its multifarious 
interactions with the host in human health and disease, is becoming increasingly 
relevant and crucial for yielding better and more tractable medical solutions.  
 
One important ailment of the gut affecting the developed world today is colorectal 
cancer (CRC). The dysfunction of APC, which is observed in an overwhelming number 
of colorectal adenomas and adenocarcinomas, is widely accepted to play an 
instrumental role in CRC. As APC is a major scaffolding protein regulating the 
canonical Wnt/β-catenin signaling cascade, initial studies have proposed that the 
consequent constitutive activation of β-catenin (arising from APC inactivation) is the 
underlying mechanism driving early transformation of the colonic epithelium.191,192 
However, subsequent investigations have reported the lack of nuclear β-catenin 
accumulation in early adenomas,193,194 suggesting that other ‘modifiers’ are required to 
fuel the canonical pathway during tumorigenesis. As such, it is highly pertinent to 
identify the potential ‘modifiers’ and assess their contributions to the development and 
progression of CRC.    
 
From our recent investigations of the APCMin/+ mouse model of CRC, we have learnt 
the integral role of gut microbiota in fueling a positive feedback channel that facilitates 
chronic inflammatory processes, thereby promoting intestinal tumor growth. While it 
may be interesting for future investigators to identify the relevant microbial species 
driving this dysbiosis-associated inflammation and examine their key regulatory 
elements, we have highlighted at least two signaling mechanisms that are aberrantly 
activated during disease pathogenesis in a genetically predisposed environment. These 
two major pro-oncogenic signaling nodes, the JNK-c-Jun/AP-1 and JAK/STAT3 
pathways, represent potential targets for the therapeutic intervention of CRC and 
colitis-associated cancer (CAC) progression.  
 
The phosphorylation of c-Jun, has been shown to interact with the canonical Wnt/β-
catenin signaling cascade through transcriptional cooperation with TCF4.35 
Furthermore, our studies as well as others have implicated its causal contribution in 
intestinal tumorigenesis.35,75 Thus, the inhibition of phospho-c-Jun-TCF4 interaction 
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appears to be a promising treatment strategy for human intestinal cancer. For instance, 
it would be interesting to determine the therapeutic effect of JNK inhibitors or small-
molecule inhibitors of down-stream effectors of the c-Jun/AP-1 activation pathway on 
the disease progression of CRC. However, as JNK signaling and the activation of c-Jun 
have been suggested to affect progenitor cell proliferation and migration in intestinal 
crypts,75 the long-term inhibition of JNK-c-Jun/AP-1 signaling is not recommended due 
to its possible impact on normal intestinal regeneration.  
 
Meanwhile, the JAK/STAT3 signaling pathway is also a relevant target for the 
treatment of inflammation-associated colorectal cancers. As we have observed STAT3 
activation predominantly in the infiltrating myeloid cells of colorectal adenomas and 
myeloid cells appear to be a major source of tumor-promoting IL-6, whose production 
is also dependent on STAT3 activation,63 it would be useful to develop efficient 
methods of targeting STAT3 phosphorylation specifically in these TAMs. Furthermore, 
the inhibition of STAT3 signaling in these immune cells can also elicit anti-tumor 
immunity in the host through triggering an intrinsic immune-surveillance system as 
demonstrated in mouse studies.53 This site-specific therapeutic strategy may be more 
beneficial to the patient as compared to the traditional ‘bulldozer’ treatment methods 
that destroy normal tissues and weaken the immune system in the process of tumor cell 
killing. 
 
Although we did not address the role of constitutive STAT3 activation in tumor 
epithelial cells in our study, it appears to play a significant role in the development of 
CAC tumors62,63 and thus should be considered as a potential target for the treatment of 
IBD-associated colon cancer. However, great caution should be taken in the long term 
use of STAT3 inhibitors, whether it is targeting the epithelial or myeloid compartments, 
in view of the important biological functions IL-6 and other STAT3 effectors have in 
the maintenance of normal intestinal epithelial homeostasis and reparative processes, as 
well as in the development of hematopoietic cells. For instance, the inactivation of 
STAT3 in immune cells of both the myeloid and lymphoid lineages resulted in the 
development of an IBD-like intestinal inflammation and malignant tumor formation in 
mice.195 In addition, the conditional ablation of STAT3 in intestinal epithelial cells 
appeared to promote tumor progression at later stages in APCMin/+ mice,196 suggesting 
that STAT3 may negatively regulate intestinal cancer progression. As such, targeting 
the STAT3 or even the c-Jun/AP-1 pathways as a therapeutic approach for CRC may 
be context dependent and can lead to very distinct consequences at different stages of 
tumor development. 
 
While we addressed the tumor promoting role of gut microbiota-associated interactions 
during inflammation-driven intestinal tumorigenesis, our studies also revealed an 
unrecognized role for a major host-microbe signaling component, the TLR4 pathway, 
in the suppression of spontaneous tumorigenesis. In particular, the unexpected 
modulation of Cox-2/PGE2 signaling by constitutive activation of TLR4 in intestinal 
epithelial cells and the corresponding up-regulation of apoptosis in APCMin/+ tumors 
illustrate the multi-faceted nature of microbial signaling in the regulation of tumor cell 
survival and death. Although the recognition of microbial ligands by TLRs can initiate 
inflammatory responses that are cancer promoting, the protective host defense or 
antimicrobial mechanisms launched by TLRs can in turn drive potent anti-tumor 
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responses as well. Through the manipulation of TLR4 signaling in an inflammation-
independent fashion, our findings suggest a physiological role of TLR4 activation in 
the inhibition of aberrant cell growth in a genetically predisposed environment. These 
results are also consistent with the data from other groups demonstrating the tumor 
surveillance or elimination mechanisms elicited by TLR4 activation.150,197  
 
Thus, the prospect of using TLR4 ligands or probiotics for reducing cancer risk in IBD 
patients or genetically susceptible individuals, and/or improving the disease outcome of 
CRC patients looks promising. In fact, the notion that gut microbiota can regulate 
health and disease was put forth by Élie Metchnikoff more than a century ago, where 
he hypothesized that beneficial microbes could replace harmful ones.79 Accumulating 
evidence from animal models and clinical studies in the recent years has demonstrated 
the beneficial efficacy of probiotics in the treatment of various ailments including 
diarrhea, allergic disorders, gastroenteritis and IBD.198 In addition, the use of fecal 
microbiota transplantation (or ‘fecal bacteriotherapy’) in the treatment of recurrent 
Clostridium difficile infection appeared to be effective in resolving symptoms such as 
diarrhea.199 These studies suggest that gastrointestinal, immune or even metabolic 
disorders arising from microbial dysbiosis can be ameliorated through restoration of a 
healthy, stable gut microbiota. Moreover, using microbial ligands, beneficial microbial 
strains or fecal microbiota transplantation as a therapeutic strategy may eventually be 
more superior to antibiotics treatment, which can disrupt the native microbiota and 
promote colonization of resistant bacterial strains. 
 
The therapeutic exploitation of the gut microbiota may also be applicable in the 
promotion of intestinal regeneration following injury. Although we did not address the 
role of constitutive TLR4 activation in intestinal regeneration in our studies, the 
increased proliferative potential of CD4-TLR4 intestinal crypt-villus organoids as well 
as their increased expression of markers of all secretory cell lineages of the gut strongly 
suggests the enhanced regenerative capacity of TLR4-active epithelia in the event of 
injury-related crypt loss. While host-microbe interactions play an integral role in the 
regulation of intestinal homeostasis and tumorigenesis, our infectious colitis model 
studies further reveal the significant impact of enteric microbial pathogens on the host’s 
innate immune and antimicrobial defenses, which can elicit potent inflammatory 
responses in the gut that further potentiates disease severity. As such, better 
understanding and manipulation of the host mechanisms that are triggered by enteric 
pathogens may be a good strategy to limit disease pathogenesis and combat infections. 
In addition, the epigenetic regulation of specific patterns of gene expression represents 
yet another aspect of therapeutic targeting for the future management of cancer, 
inflammatory as well as infectious diseases.   
 
Meanwhile, the recent advent of improved methods for the long-term in vitro culture 
and expansion of primary intestinal epithelial organoids and adenomas from the mouse 
and human,139 as well as the feasibility of virally mediated gene transfer in some of 
these organoids systems,200 offers a major advancement for translational research. For 
instance, it would now be possible to test the therapeutic efficacy of potential anti-
cancer drugs on human CRC clinical samples. The identification of novel cancer targets 
through genetic manipulation studies of primary organoid systems also holds great 
promise in the near future. In retrospect, some of the ex vivo stimulation assays 
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described in the first paper would have been carried out more efficiently if some of 
these methods were available earlier. 
 
The crucial importance of the gut microbiota in human health and disease has been 
rapidly emerging in the recent years. This is well illustrated by a number of reviews 
describing the interactions between the host immune system and gut microbiota, 
including how microbial composition and diversity can shape the adaptive immune 
system and influence the development of various human diseases such as IBD, 
autoimmune disorders and obesity.201,202 Moreover, the discovery of a commensal 
microbial species that can promote intestinal tumorigenesis during colitis highlights 
how intestinal inflammation can alter microbial composition and activity, promoting a 
dysbiotic microbiota which in turn impacts on the host’s health.203 In light of the recent 
advances in the understanding host-microbiota interactions and their impact on human 
health, it has been extremely meaningful for me to put this thesis together and I hope 
that our studies will ultimately contribute to the biomedical field.  Nonetheless, it has 
been an exciting and insightful learning experience to participate actively in all four 
studies and I am grateful for the valuable lessons and knowledge gained from this PhD 
journey.   
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